Gold prices edge higher on raised Fed rate cut hopes
CHARLOTTE - Dentsply Sirona Inc. (NASDAQ:XRAY) announced Monday that Daniel Scavilla will become President and Chief Executive Officer effective August 1, 2025, replacing Simon Campion who is departing the company on July 31.
Scavilla, who joined Dentsply Sirona’s Board of Directors in February 2025, brings over 30 years of experience in the medical technology and pharmaceutical industries. He recently served as President and CEO of Globus Medical, where he led the $3 billion acquisition of NuVasive and created the world’s second-largest spine technology company.
Before his tenure at Globus Medical, Scavilla spent 28 years in various financial and operational leadership roles at Johnson & Johnson.
Gregory T. Lucier, Chairman of the Board, said Scavilla’s appointment "underscores the Board’s strong and unwavering commitment to delivering enhanced value to shareholders and positioning Dentsply Sirona for future success."
Campion, who served as CEO for three years, has also stepped down from the company’s Board of Directors. Scavilla will continue to serve as a director but will no longer participate in the Board’s Audit and Finance Committee.
In conjunction with the leadership announcement, Dentsply Sirona released preliminary financial results for the second quarter of 2025, expecting to report net sales of approximately $935 million and adjusted earnings per diluted share between $0.50 and $0.52.
The company reaffirmed its full-year 2025 outlook previously provided in its May 8 earnings release. Complete second quarter results are scheduled to be reported on August 7, 2025.
Dentsply Sirona manufactures professional dental products and technologies, offering dental and oral health products under various brands. The information in this article is based on a company press release statement.
In other recent news, Globus Medical reported preliminary second-quarter 2025 sales results, revealing an expected revenue of approximately $745.3 million, marking an 18.4% increase compared to the same period last year. The company also reaffirmed its full-year 2025 guidance, projecting revenue between $2.80 billion and $2.90 billion. In a strategic move, Keith Pfeil has been appointed as the new President and CEO, effective July 18, 2025, succeeding Daniel Scavilla. Additionally, Globus Medical expanded its navigation capabilities with the introduction of the DuraPro oscillating system, aimed at enhancing spine surgery procedures. Piper Sandler maintained its Overweight rating on Globus Medical, noting some challenges but expressing confidence in the company’s long-term value. Conversely, BTIG downgraded the stock from Buy to Neutral, citing concerns about the core Spine business following the integration of NuVasive. JMP analysts maintained a Market Perform rating, highlighting Globus Medical’s robust cash flow and debt-free status after repaying obligations from the NuVasive merger. These developments reflect a dynamic period for Globus Medical as it navigates both opportunities and challenges in the medical device sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.